Anatomía Patológica Algunas consideraciones sobre la inmunohistoquímica en el diagnóstico diferencial entre Mesotelioma y Adenocarcinoma
Referencias
Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesotelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Sem in Diag Pathol 1992, 9: 124-140
Ordoñez NG. In search of a positive immunohistochemical marker for mesothelioma: an update. Adv Anat Pathol 1998, 5: 53-60
Hasleton P, King J. Malignant pleural Mesotelioma. Curr Diag Pathol 1999, 5: 991-1005
Enticknap JB, Smither J. Peritoneal tumors in asbestosis. Brt J Ind Med 1964, 21: 20-31
Acheson RD, Gardner MJ, Pippard EC y col. Mortality of two groups of women who manofacture gas masks from cleyostile and crocidolite asbestos: a 40 years follow-up. Brt J Ind Med 1982, 39: 344-348
Peto J, Hodgson J, Mattheus F, Jones J. Continuing increase in mesothelioma mortality in Britain. Lancet 1995, 345: 535-539
Fisher ER, Helstron R. The periodic acid Schiff reaction as an aid in the diagnosis of malignant mesothelioma. Cancer 1960, 13: 837-841
García Tamayo J. Aspectos ultraestructurales de la patología tumoral. Invest Clin 1982, 3: 123-215
Wagner JC, Munday DE, Harrington JS. Histochemical demonstration of hyaluronic acid in human mesotheliomas. J Pathol Bacteriol 1985, 16: 50-55
King JE, Hasleton PS. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology 2001, 38: 471-476
Brown RW, Clark GM, Tandon AK, Craig AD. Multiple-marker immunohistochemical phenotypes distinghishing malignant pelural mesotheliomas from pulmonary adenocarcinoma. Hum Pathol 1993, 24: 347-354
Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW. Differentiation of adenocarcinoma of te lung and malignant mesothelioma: predictive value and reproductibility of immunoreactive antibodies. Histopathol 1994, 25: 431-437
Sheibani K. Immunopathology of malignant mesothelioma. Human Pathol 1994, 25: 219-220
Sheibani K, Shin SS, Kezirian J, Weeiss LM. BER-EP4 as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J. Surg Pathol 1991, 15: 779-784
Gaffey MJ, Mills SE, Swanson PE y col. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors and malignant mesotheliomas. Am J Surg Pathol 1992, 16: 593-599
García-Prats MD, Caballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI. Acomparative evaluation of immunohistochemcal markers for the differential diagnosis of malignant pleural tumors. Histopathol 1998, 32: 462-472
González-Lois C, Ballestin MT, Sotelo MT, Lopez Rios F, García Prats MD, Villena V. Combined use of novel epithelial (MOC-31) and mesothelial (HMB-1) immunohistochemical markers for optimal fist line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathol 1001, 38: 528-534
Peralta-Soler A, Knudsen KA, Jaurand MC. The differential expresión of N-Cadherin and E-Cadherin distinghishes pleural mesotheliomas from lung adenocarcinoma. Human Pathol 1995, 26: 1363-1369
Han A, Peralta-Soler A, Knudsen K y col. Differential expresión of N-Cadherin in pleural mesotheliomas and E-Cadherin in lung adenocarcinomas. Hum Pathol 1997, 28: 641-645
Ordóñez N. Value of thyroid transcription factor-1, E-Cadherin, BG8, WT1 and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and non-pulmonary adenocarcinoma. Am J Surg Pathol 2000, 24: 598-606
Amin KM, Litzky LA, Smythe WR, Moone AM, Morris JM, Mews DJ. Wilms´ Tumor 1 susceptibility ( WT1) gene products are seletively expressed in malignant mesothelioma. Am J Pathol 1995, 146: 344-356.
Attanoos R, Dojcinov S, Webb R, Gibbs A. Antimesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathol 2000, 37: 224-231
Ordóñez N. Value of cytokeratin 5/6 in distinguishing epitehlial mesothelioma of the pleura from adenocarcinoma. Am J Surg Pathol 1998, 22: 1215-1221
Henderson D, Shilikin K, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ. Am J Clin Pathol 1998, 110: 397-404
King JE, Hasleton PS. Immunohistochemistry in the diagnosis of malignant Mesothelioma. Histopathol 2001, 38: 471-476
García Tamayo J, Ruíz ME. Hemangioma histiocitoide y hemangioendotelioma epitelioide. Estudio histológico, inmunohistológico y ultraestructural. Patología (Esp) 1989, 22:170-180
Lin BT, Colby T, Gown AM, Hammar SP, Merthens RB, Churg A y col. Malignant vascular tumors of the serous membranes mimick mesothelioma. A report of 14 cases. Am J Surg Pathol 1996, 20: 1431-1439
Orosz Z, Nagy P, Szentirmay Z, Zalatnai A, Hauser P. Epithelial mesothelioma with deciduoid features. Virchos Arch 1999, 434: 263-266
Friersoon HF, Bellafiore FJ, Gaffey MJ, ScottMcCary W, Innes DJ, Williams ME. Cytokeratina in Anaplastic Large Cell Lymphoma. Modern Pathol 1994, 7: 317-321
Oates J, Edwards C. HBM-1, MOC 31, WT1 and Calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000, 36: 341-347
Collins C, Ordoñez ND, Schaefer R y col. Trombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992, 141: 927-933
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit
